BioDelivery Sciences International, Inc. Overview
Pro stress-test →BioDelivery Sciences International is a specialty pharmaceutical company focused on chronic pain management and related conditions. The company leverages its proprietary BioErodible MucoAdhesive (BEMA) drug-delivery technology platform to develop and commercialize pharmaceutical products, with flagship products including Belbuca (buprenorphine) and Symproic (naldemedine).
Strategic Profile
Pro stress-test →BDSI competes in the specialty pharma space with differentiated drug-delivery technologies rather than first-to-market compounds. The company has secured patent protection for its key asset Belbuca with exclusivity extending to 2032 against generic competition. The company remains focused on expanding its portfolio and improving patient access to chronic pain treatments across various therapeutic modalities.
Competitive Landscape
Pro stress-test →BDSI competes against major pharma companies and specialized pain-management competitors including Collegium Pharmaceutical (opioid products), Purdue Pharma legacy competitors, and generic manufacturers. Differentiation relies on BEMA technology and established commercial relationships rather than blockbuster drug development. Larger competitors with broader portfolios and manufacturing scale create pricing and market-access pressures.
Industry Context
BioDelivery Sciences International, Inc. operates in Specialty pharmaceuticals for chronic pain management.
Key facts
Founded: 1997 · Headquarters: Raleigh, North Carolina, US · Employees: ~200 (as of 2021) · Revenue: N/A · Market cap: ~$577M (as of March 2022)